<DOC>
	<DOCNO>NCT00007865</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy combine rituximab treat patient recurrent refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Rituximab Treating Patients With Recurrent Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine chemosensitivity rate patient recurrent refractory non-Hodgkin 's lymphoma treat ifosfamide , carboplatin , etoposide ( ICE ) combination rituximab . - Determine whether addition rituximab change toxicity profile ICE chemotherapy regimen patient . OUTLINE : Patients receive rituximab IV day 1 , 8 , 15 ifosfamide IV 1 hour , etoposide IV 2 hour , carboplatin IV day 2-4 . Treatment continue every 21 day 2 course absence disease progression unacceptable toxicity . Patients candidate autologous stem cell transplantation may receive 1-4 course chemotherapy without rituximab . Patients follow 1 month . PROJECTED ACCRUAL : A total 19-39 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory Bcell nonHodgkin 's lymphoma CD20 positive Bidimensionally measurable evaluable disease No myelodysplastic syndrome chronic myeloid leukemia PATIENT CHARACTERISTICS : Age : 19 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy except curatively treat basal cell carcinoma , squamous cell carcinoma , carcinoma situ cervix No active serious infection No concurrent serious medical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow peripheral blood stem cell transplantation nonHodgkin 's lymphoma Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid except transient administration antiemetic Concurrent nonsteroidal hormonal therapy allow nondisease related condition ( e.g. , insulin diabetes ) Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent investigational therapy No concurrent antitumor agent</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>